635.2500 -13.20 (-2.04%)
NSE May 08, 2025 15:31 PM
Volume: 201.8K
 

635.25
-2.04%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd.'s price crossed below 50Day SMA today
More from Strides Pharma Science Ltd.
Recommended